Y-mAbs Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Y-mAbs Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q1 2021 to Q2 2024.
  • Y-mAbs Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending June 30, 2024 was $22.2M, a 16.1% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $22.2M +$3.07M +16.1% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $20.6M +$1.89M +10.1% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $22.5M +$9.92M +79.2% Dec 31, 2023 10-Q 2024-08-12
Q3 2023 $18.9M +$9.62M +104% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $19.1M +$11.9M +165% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $18.7M +$9.38M +101% Mar 31, 2023 10-Q 2023-05-08
Q4 2022 $12.5M +$4.82M +62.5% Dec 31, 2022 10-K 2024-02-29
Q3 2022 $9.25M +$1.99M +27.4% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $7.21M -$1.31M -15.4% Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $9.32M +$3.33M +55.5% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $7.71M Dec 31, 2021 10-K 2023-03-30
Q3 2021 $7.26M Sep 30, 2021 10-Q 2021-11-04
Q2 2021 $8.52M Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $6M Mar 31, 2021 10-Q 2021-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.